Am J Otolaryngol. 2026 Nov 17;48(1):105000. doi: 10.1016/j.amjoto.2026.105000. Online ahead of print.

ABSTRACT

PURPOSE: Mandibular advancement devices (MADs) are an established treatment for obstructive sleep apnea (OSA), but reliable predictors of response remain limited. Positional OSA (POSA) has been proposed as a favorable phenotype. This study evaluated whether positional phenotype influences respiratory outcomes and treatment success in patients treated with MAD.

METHODS: This multicenter retrospective cohort study included 82 consecutive patients with OSA treated with MAD across six tertiary sleep centers. Baseline and follow-up home sleep apnea tests performed at least 6 months after completion of MAD titration were analyzed. POSA was defined according to Cartwright’s criteria as a supine apnea-hypopnea index (AHI) at least twice the non-supine AHI. Outcomes included changes in respiratory parameters and treatment success according to Sher’s criteria (≥50% AHI reduction and post-treatment AHI <20 events/h).

RESULTS: Fifty patients had POSA and 32 had non-POSA. MAD therapy significantly improved total AHI, oxygen desaturation index, and oxygenation parameters in both groups. Treatment success occurred in 42/50 POSA patients (84.0%) and 30/32 non-POSA patients (93.8%; p = 0.332). Reductions in total AHI were also comparable between groups (19.19 ± 15.50 vs 24.14 ± 19.60 events/h; p = 0.232). Likewise, rates of achieving AHI <10 and <5 events/h did not differ significantly between groups. Positional phenotype was not significantly associated with treatment success.

CONCLUSIONS: MAD therapy was associated with respiratory improvement regardless of positional phenotype. These findings do not support using POSA alone as a criterion for selecting candidates for MAD therapy. Larger prospective studies are required to confirm these results.

PMID:43056883 | DOI:10.1016/j.amjoto.2026.105000